CEO Interview: AmexDrug Corporation - Jack Amin

• On 2:47 pm EST, Monday November 2, 2009

67 WALL STREET, New York - November 2, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76-page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Small-Cap Specialty Pharma - Patent Expiration - Pending Health Care Reform - Cultivating And Expanding R&D Pipelines - Chinese Drug Manufacturers - Brisk M&A Activity - Indian Pharma VS. U.S. Pharma - Competition From Generics - FDA Approval Process - Clinical Research Outsourcing Market - Stem Cell-Based Technology - Cancer Radiation Therapy - Expansion Into Asian Markets - Traditional Chinese Medicine VS. Western Medicine In Chinese Pharma

Companies include: Aeolus Pharmaceuticals (AOLS.OB); Nutra Pharma (NPHC.OB); Quick-Med Technologies (QMDT.OB); Abbott Labs (ABT); Alexza Pharmaceuticals (ALXA); AmexDrug Corporation (AXRX.OB); Aurobindo Pharma (AUROBINDOP.BO); BioClinica (BIOC); BioPharm Asia (BFAR.OB); Biocon (BIOCON.BO); Cephalon (CEPH); China Sky One Medical, Inc. (CSKI); Claris Lifesciences (CLARICH.BO); Cortex Pharmaceuticals (COR); Daiichi Sankyo (DSKYF.PK); Dr.Reddy's (RDY); Elan (Elan); Eli Lilly (LLY); Forest (FRX); GeoPharma (GORX); Glaxo (GSK); Glenmark (GLENMARK.BO); Johnson & Johnson (JNJ); Lupin (LUPINSL.BO); Mannatech (MTEX); Matrix Laboratories (ATRIXLAB.BO); Medical Nutrition (MDNU); Merck KGaA (MKGAY.PK); Mylan (MYL); NeoStem (NBS); Novartis (NVS); Pfizer (PFE); Piramal Healthcare (PIRAMALHE.BO); Provectus Pharmaceuticals (PVCT.OB); Ranbaxy (RANBAXY.BO); Salix Pharmaceuticals (SLXP); Shire (SHPGY); Telik (TELK); Winston Pharmaceuticals (WPHM.OB).

In the following brief excerpt from the 76-page report, Jack Amin, CEO of AmexDrug Corporation, discusses the outlook for the sector and for investors.

JACK AMIN has served as the President, Secretary, Treasurer and as a Director of AmexDrug since April 2000. He holds a Bachelor of Science in electronic engineering from Western States College of Engineering in 1982. Since 1980 Mr. Amin has been engaged in various capacities, including sales and management within the pharmaceutical industry. Mr. Amin has served as the President, Chief Executive Officer and Director of Amexdrug's wholly owned subsidiary, Allied Med, Inc., a company which he founded in 1997.

TWST: Let's begin with a brief overview of the history and evolution of AmexDrug.

Mr. Amin: AmexDrug Corporation (AXRX.OB) is actually a vertically integrated pharmaceutical and cosmeceutical manufacturing company. We have subsidiaries, such as BioRX Pharmaceuticals, Allied Medical Wholesale, Dermagen, Inc., which develop, manufacture, market and distribute pharmaceutical and innovative skin care products within the United States.

TWST: Please explain the makeup of your customer base and who your direct competition is today.

Mr. Amin: Basically, our customer base are independent pharmacies, wholesalers and chain drug stores. Within a year, we're planning to distribute our product, which is trademarked as SPONIX within the retail markets such as CVS, Kroger's, Walgreens. We would like to get our products within those stores within next year or so.

TWST: How has the company been managing during this downturn? You're based on the West Coast, is that right?

Mr. Amin: That's correct. We're in Los Angeles, California. Actually, we're doing very well; we're doing better than last year and the year before. Our sales are going up, according to our last quarter. We had, I believe, a 50% to 60% jump on our revenue, and this quarter we're going to have another jump. We're working against the downturn. So we're going up, our sales are going up, our margin is going up and we have added prescription packaging products to our line as well. We have had more distribution to stores, to independent pharmacies nationwide as we're picking up a few smaller chain drug stores. So we've been doing pretty well.

TWST: As you look ahead over the next several years, what specific trends do you see emerging that you'll want to stay on top of?

Mr. Amin: Actually, we are developing more products. They're all innovative products. Right now we have 12 to 14 products on hand. We have three to four more products in the channel that are coming out. We're adding more products for health care issues, and we should have about 25 products by the end of 2010 - 25 to 30 actually. So far we have done very well, and we're expecting our revenue to go higher within the next six months.

TWST: Are you as well positioned as you would like to be to follow through on any opportunities that may come?

Mr. Amin: Actually, we're very pleased with the cash flow that we have at this time. Other than that, we can still grow very nicely, and we shouldn't have any problems. We should be okay unless we want to have a big jump towards the market share of the big chain drug stores.

TWST: Have you incorporated any international aspects into your business or strategies respect to Canada, Mexico or any other international markets?

Mr. Amin: Actually, we're working in the Asian market. So the Asian market could be good. We already have some interest in Malaysia and from there it's to other parts of Asia. We're expecting that to happen within the next few months. We have had contacts Brazil and Mexico - there's a good possibility for that as well.

The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This 76-page special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online .

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.

For Information on subscribing to The Wall Street Transcript, please call 800/246-7673

Buzz up!